Testing for t(3;8) in MYC/BCL6-rearranged large B-cell lymphoma identifies a high-risk subgroup with inferior survival-Reference-Cited by-同舟云学术

Testing for t(3;8) in MYC/BCL6-rearranged large B-cell lymphoma identifies a high-risk subgroup with inferior survival

Published:2024-07-04 Issue:1 Volume:144 Page:113-117
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Maybury Bernard D.¹^ORCID,James Lisa²,Phillips Neil³,Venkatadasari Indrani⁴,Qureshi Iman⁵,Riley James¹,Talbot Georgina³,Moosai Shivir⁶⁷^ORCID,Giles Hannah³,Chadderton Nicola²,Dowds James²,Rakesh Pallav⁸,Crosland Henry¹,Haslam Aidan¹,Lane Sarah⁹,Vega Gonzalez Monica¹⁰,Davies David⁶,Cherian George⁹,Shenouda Amir⁸,Kaudlay Praveen⁴,Starczynski Jane²,Rudzki Zbigniew²^ORCID,Chaganti Sridhar¹

Affiliation:

1. 1Department of Haematology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

2. 2Department of Histopathology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

3. 3Department of Haematology, University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, United Kingdom

4. 4Department of Haematology, The Royal Wolverhampton NHS Trust, Wolverhampton, United Kingdom

5. 5Department of Haematology, Worcestershire Acute Hospitals NHS Trust, Worcester, United Kingdom

6. 6Department of Haematology, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, United Kingdom

7. 7Department of Haematology, University Hospitals Coventry and Warwickshire, Coventry, United Kingdom

8. 8Department of Haematology, The Dudley Group NHS Foundation Trust, Dudley, United Kingdom

9. 9Department of Haematology, Shrewsbury and Telford Hospital NHS Trust, Shrewsbury, United Kingdom

10. 10Department of Haematology, Walsall Healthcare NHS Trust, Walsall, United Kingdom

Abstract

Abstract A reciprocal t(3;8) BCL6::MYC fusion is common in large B-cell lymphoma (LBCL) with MYC and BCL6 disruption. These pseudo–double-hit cases are not adverse, whereas t(3;8)−MYC/BCL6 lymphoma has an inferior prognosis relative to other MYC-rearranged LBCL.

Publisher

American Society of Hematology

Link

https://ashpublications.org/blood/article-pdf/144/1/113/2233502/blood_bld-2024-024048-main.pdf

Reference17 articles.

1. MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study;Copie-Bergman;Blood,2015

2. Prognostic significance of MYC rearrangement and translocation partner in diffuse large B-cell lymphoma: a study by the Lunenburg lymphoma biomarker consortium;Rosenwald;J Clin Oncol,2019

3. BCL6 rearrangement indicates poor prognosis in diffuse large B-cell lymphoma patients: a meta-analysis of cohort studies;Li;J Cancer,2019

4. A retrospective study of MYC rearranged diffuse large B-cell lymphoma in the context of the new WHO and ICC classifications;El-Sharkawi;Blood Cancer J,2023

5. Comparing clinical characteristics and outcomes of MYC and BCL6 double hit lymphoma (DHL- BCL6) with other aggressive B-cell lymphomas: understanding the impact of new WHO and International Consensus Classifications [abstract];Khurana;Blood,2023

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Transferrin: the iron transporter takes control;Blood;2024-07-04